Elizabeth E. Reed - 17 Feb 2026 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Role
Chief Legal Officer and GC
Signature
/s/ Elizabeth E. Reed
Issuer symbol
TVTX
Transactions as of
17 Feb 2026
Net transactions value
-$87,515
Form type
4
Filing time
19 Feb 2026, 16:10:04 UTC
Previous filing
05 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
REED ELIZABETH E Chief Legal Officer and GC C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DR., SUITE 300, SAN DIEGO /s/ Elizabeth E. Reed 19 Feb 2026 0001283303

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TVTX Common Stock Options Exercise $190,800 +10,000 +9.5% $19.08 115,211 17 Feb 2026 Direct
transaction TVTX Common Stock Sale $156,195 -5,679 -4.9% $27.50 109,532 17 Feb 2026 Direct F1, F2
transaction TVTX Common Stock Sale $122,120 -4,321 -3.9% $28.26 105,211 17 Feb 2026 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TVTX Employee stock option (right to buy) Options Exercise $0 -10,000 -33% $0.000000 20,000 17 Feb 2026 Common Stock 10,000 $19.08 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 4, 2017 with an expiration date of January 4, 2027.
F2 The weighted average sale price for the transaction reported was $27.504, and the range of prices were between $27.01 and $27.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3 The weighted average sale price for the transaction reported was $28.262, and the range of prices were between $28.09 and $28.50. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F4 The stock option is fully vested and exercisable.